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The highly unnatural fatty acid profile of cells in culture 
Abstract 
The fatty acid profile of cells in culture are unlike those of natural cells with twice the monounsaturated 
(MUFA) and half the polyunsaturated fatty acids (PUFA) level (Mol%). This is not due to cell lines primarily 
being derived from cancers but is due to limited access to lipid and an inability to make PUFA de novo as 
vertebrate cells. Classic culture methods use media with 10% serum (the only exogenous source of lipid). 
Fetal bovine serum (FBS), the serum of choice has a low level of lipid and cholesterol compared to other 
sera and at 10% of media provides 2-3% of the fatty acid and cholesterol, 1% of the PUFA and 0.3% of the 
essential fatty acid linoleic acid (18:2n-6) available to cells in the body. Since vertebrate cell lines cannot 
make PUFA they synthesise MUFA, offsetting their PUFA deficit and reducing their fatty acid diversity. 
Stem and primary cells in culture appear to be similarly affected, with a rapid loss of their natural fatty 
acid compositions. The unnatural lipid composition of cells in culture has substantial implications for 
examining natural stems cell in culture, and for investigations of cellular mechanisms using cell lines 
based on the pervasive influence of fats. 
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The fatty acid profile of cells in culture are unlike any natural cell with twice the 
monounsaturated (MUFA) and half the polyunsaturated fatty acids (PUFA) of natural cells 
(Mol%). This is not due to cell lines primarily being derived from cancers but due to limited 
access to lipid and inability to make PUFA de novo as vertebrate cells. Classic culture 
methods use media with 10% serum (the only exogenous source of lipid). Fetal bovine serum 
(FBS), the serum of choice has a low level of lipid and cholesterol compared to other sera and 
at 10% of media provides 2-3% of the fatty acid and cholesterol, 1% of the PUFA and 0.3% 
of the essential fatty acid linoleic acid (18:2n-6) available to cells in the body. Since 
vertebrate cell lines cannot make PUFA they synthesise MUFA, offsetting their PUFA deficit 
and reducing their fatty acid diversity. Stem and primary cells in culture appear to be similarly 
affected, with a rapid loss of their natural fatty acid compositions. The unnatural lipid 
composition of cells in culture has substantial implications for examining natural stems cell in 















130mgP/g	of	cell.	SAT, MUFA and PUFA (unless otherwise stated) as used in this 
manuscript refer to the derivatized fatty acid esters formed from total lipid extracts of cells, 

























































































































































































































































































































































































































































	 	 	 	 	
Bovine+	S	 Fetal	 3.1	 26.3	 14.5	 11.9	 21.0	 	 3.6	 	 1.8	 4.4	 	 6.8	 1.0	 2.6	 3.3	 43.9	 32.9	 23.5	 72	 [44]	
Bovine+	S	 Fetal	 6.1	 22.7	 12.2	 12.8	 20.4	 6.8	 5.5	 1.0	 	 3.6	 0.4	 	 0.7	 	 1.8	 46.0	 33.2	 19.8	 40	 [28])		
Bovine+	S	 Fetal	 1.4	 21.9	 12.4	 6.8	 27.7	 6.3	 6.2	 	 	 9.6	 0.3	 	 	 	 3.5	 35.7	 34.6	 25.9	 66	 [96]	
Bovine+	S	 Fetal	 4.1	 27.3	 12.6	 12.9	 19.5	 	 5.6	 	 2.0	 7.7	 	 1.8	 0.8	 1.9	 3.0	 44.0	 32.4	 22.8	 64	 [46]	








































Mouse+	S	 Adult	 3.9	 18.2	 13.8	 6.8	 13.6	 0.3	 18.1	 0.1	 1.6	 17.6	 0.3	 	 0.1	 0.1	 5.4	 35.9	 20.4	 43.6	 104	 [107]	
Rat*	P	 Adult	 1.4	 25.2	 17.3	 3.6	 6.7	 0.3	 18.4	 	 0.7	 21.1	 0.2	 	 0.1	 0.5	 3.3	 43.9	 10.3	 44.6	 103	 [108]	
Rabbit*	S	 Adult	 1.0	 18.5	 23.9	 2.8	 12.2	 	 24.4	 0.9	 	 10.5	 3.7	 	 0.4	 	 1.7	 43.4	 15.0	 41.6	 74	 [109]	
Cat+	S	 Adult	 	 10.7	 14.8	 	 20.6	 	 38.6	 	 	 7.7	 	 	 	 	 	 25.5	 27.2	 46.3	 62	 [110]	
Cheetah+	S	 Adult	 3.7	 31.9	 49.0	 1.0	 4.1	 	 6.8	 0.2	 	 1.2	 0.2	 	 0.1	 	 	 84.6	 5.1	 8.5	 11.5	 [111]	
Dog+	P	 Adult	 1.0	 13.3	 21.2	 4.0	 14.2	 1.1	 23.8	 	 0.9	 13.4	 0.4	 	 2.3	 2.0	 2.3	 35.5	 18.2	 46.2	 98.8	 [112]		
Pig+	S	 Adult	 	 16.9	 13.9	 2.5	 28.4	 	 20.9	 	 	 10.6	 0.4	 	 	 	 0.5	 30.8	 30.9	 32.4	 56	 [96]	
Human*	S	 East	Asian	 	 29.9	 13.6	 	 10.9	 0.81	 20.9	 	 2.6	 8.9	 0.3	 	 1.0	 0.8	 3.0	 43.5	 10.9	 38.3	 78	 [113]	
Human+	P		 Caucasian	 1.5	 23.4	 7.0	 2.6	 21.8	 1.4	 33.1	 0.2	 	 5.6	 1.1	 	 0.6	 0.3	 1.3	 31.9	 24.4	 43.6	 66	 [11]	
Cow+	S	 Calf	 0.3	 15.2	 14.2	 2.4	 16.9	 0.6	 46.4	 	 	 3.6	 1.1	 	 	 	 0.4	 30.5	 18.8	 50.5	 60	 [96]	
Horse+	P	 Adult	 3.1	 21.3	 21.3	 2.2	 10.8	 0.5	 33.5	 	 0.7	 1.2	 1.0	 0.2	 	 	 0.8	 45.7	 13.0	 37.9	 46	 [114]	
Elephant+	P	 Adult	 3.2	 22.8	 10.9	 1.0	 16.0	 	 25.3	 0.4	 	 8.0	 5.5	 	 	 	 	 36.9	 17.0	 39.2	 61	 [115]	



























































































	 	 	 16:0	 18:0	 18:1	 18:2	 20:2	 20:3	 20:4	 18:3	 20:5	 22:5	 22:6	
LIVER	 Rat*	 H35	Hepatoma		 3.0	 15.0	 16.7	 20.9	 36	 0.1	 1.2	 1.2	 0.4	 2.3	 	 0.5	 1.2	 1.5	 34.7	 56.9	 8.4	 24.7	 [44]	
	 Rat*	 H35	Reuber	Hepatoma	 5.7	 18.6	 16.3	 16.1	 28.3	 2.1	 1.9	 0.9	 0.7	 4.2	 	 0.7	 1.9	 2.7	 40.6	 44.4	 15.1	 47.0	 [46]	
	 Human+		 HepG2	Carcinoma	 6.4	 37.0	 7.1	 15.6	 31.5	 	 1.5	 	 	 0.5	 	 0.4	 0.2	 0.3	 50.5	 47.1	 2.9	 6.9	 [101]	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	
KIDNEY	 Dog*	 MDCK	Proximal	Tubule	 3.9	 13.8	 16.4	 10.5	 45.3	 1.1	 2.0	 	 	 4.2	 	 	 	 1.0	 34.1	 55.8	 8.3	 21.8	 [96]	
	 Monkey*	 CV-1	Epithelia	 11.1	 24.3	 14.5	 17.1	 23.0	 	 2.5	 	 	 3.7	 	 	 	 1.5	 45.4	 39.1	 7.7	 21.1	 [117]	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	
BRAIN	&	NEURAL	 Mouse*		 HT-22	Hippocampal	 1.9	 23.3	 14.8	 19.5	 23.2	 0.6	 1.6	 	 	 8.5	 0.4	 0.6	 1.9	 2.2	 42.0	 42.7	 15.2	 48.9	 [43]	
	 Mouse*	 SN56	Septal	Neurons	 4.6	 25.9	 12.6	 18.4	 23.2	 	 2.5	 	 	 8.3	 	 0.4	 1.4	 2.4	 43.1	 41.7	 15.0	 47.4	 [43]	
	 Human*	 SH-SY5Y	Neuroblastoma	 	 37.1	 18.9	 	 23.9	 	 2.8	 	 	 11.1	 	 	 	 6.1	 56.0	 23.9	 20.0	 66.6	 [22]	
	 Human+	 CHP-212	Neuroblastoma	 4.0	 27.7	 15.3	 4.3	 26.6	 3.6	 4.6	 	 0.5	 4.4	 1.4	 0.9	 1.6	 1.6	 47.0	 30.9	 18.6	 50.5	 [60]	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	
LUNG	 Human*		 A549	Alveolar	Epithelia	 4.6	 34.2	 15.6	 10.1	 25.9	 	 2.8	 	 	 5.4	 	 	 	 1.5	 54.4	 36.0	 9.7	 26.5	 [47]	
	 Human*		 IMR90	Fetal	Lung	
Myofibroblasts	
	 19.8	 17.2	 4.6	 30.3	 0.9	 3.0	 0.3	 2.2	 8.1	 0.8	 	 2.0	 3.9	 35.4	 34.1	 21.2	 63.8	 [118]	
	 Human*	 16HBE	Bronchial	Epithelia	 40.6§	 	 	 40.4	 	 0.3	 2.1	 	 	 6.5	 	 0.6	 2.4	 3.0	 40.6	 40.4	 14.9	 49.8	 [119]	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	
BLOOD	CELLS	 Mouse+	 L1210	B-Lymphocyte	 1.9	 16.5	 22.4	 4.0	 34.4	 1.9	 2.8	 0.1	 1.2	 6.2	 1.1	 0.9	 1.4	 1.7	 40.8	 38.4	 17.3	 49.3	 [90]	
	 Mouse+	 WEHI-3	Macrophage	 2.2	 25.9	 19.5	 4.2	 37.6	 	 3.3	 	 	 5.3	 	 	 	 0.4	 47.2	 41.8	 9.0	 21.2	 [61]	
	 Mouse+	 J774A.1	Macrophage	 1.4	 33.0	 10.9	 11.5	 24.3	 	 3.6	 	 	 9.5	 	 	 	 2.9	 45.7	 35.8	 16.0	 46.6	 [61]	
	 Human+	 Jurkat	T-Lymphocyte	 8.0	 31.0	 23.8	 	 19.1	 3.0	 	 	 	 11.2	 	 	 	 4.0	 64.8	 18.9	 16.2	 55.4	 [120]	
	 Human+	 Raji	B-Lymphocyte	(CD19)	 4.4	 24.9	 20.3	 15.0	 20.1	 1.8	 3.9	 	 1.2	 4.4	 0.3	 0.6	 1.7	 2.8	 49.6	 35.1	 16.7	 47.9	 [29]	
	 Human+	 THP-1	Macrophage	 5.3	 28.8	 16.4	 15.6	 22.0	 1.7	 1.5	 	 1.0	 3.5	 0.1	 0.5	 1.4	 2.9	 50.5	 37.6	 12.6	 40.4	 [29]	




5.7	 17.4	 11.2	 17.6	 29.7	 2.1	 3.9	 	 	 2.9	 0.1	 1.0	 	 0.6	 34.3	 47.3	 9.2	 24.0	 [28]	
	 Human+	 SW-620	Colon	Carcinoma	 3.3	 28.3	 15.6	 5.6	 24.3	 2.2	 4.7	 	 1.3	 6.0	 0.8	 1.0	 1.4	 3.3	 47.2	 29.9	 22.4	 65.5	 [60]	
	 Human*	 HT29	Colonic	
Adenocarcinoma	
4.5	 24.9	 9.1	 17.3	 28.1	 	 2.2	 	 	 5.9	 	 0.7	 	 2.3	 38.5	 45.4	 11.1	 34.2	 [45]	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	
OTHER	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Larynx	 Human+		 Hep2	Larynx	 4.9	 23.2	 10.2	 19.3	 21.1	 1.6	 3.8	 6.1	 1.2	 3.0	 	 	 1.4	 4.2	 38.3	 40.4	 21.3	 58.8	 [121]	
Cervix	 Human*		 HeLa	 8.3	 48.0	 9.4	 4.0	 7.6	 	 1.4	 	 12.2	 2.2	 	 	 	 	 65.7	 11.6	 15.8	 32.4	 [122]		
Pancreas	 Rat+	 AR42J	 4.1	 29.8	 15.7	 3.7	 24.8	 	 3.2	 	 	 3.7	 3.4	 0.5	 	 1.6	 49.6	 28.5	 12.4	 30.8	 [123]	
































































































	 	 	 18:1	 18:2	 20:2	 20:3	 20:4	 18:3	 20:5	 22:5	 22:6	
LIVER	 Mouse*	 	 0.3	 17.0	 16.2	 5.9	 9.1	 2.4	 10.4	 	 2.2	 23.2	 	 0.2	 0.5	 11.8	 33.5	 15.0	 50.7	 152.2	 [15]	
	 Rat*	 Hepatocytes	(Isolated)	 0.6	 19.3	 19.1	 1.0	 10.3	 	 17.0	 	 	 23.5	 	 	 	 9.5	 39.0	 11.3	 50.0	 135.0	 [124]	
	 Rat*		 	 0.6	 14.3	 22.9	 5.1	 3.8	 0.5	 9.9	 	 0.8	 32.7	 0.1	 0.2	 0.8	 6.9	 37.8	 8.9	 52.5	 151.1	 [15]	
	 Human*	 	 5.8	 16.4	 10.2	 5.2	 9.4	 2.0	 2.0	 	 	 21.6	 1.2	 5.1	 6.4	 14.8	 32.4	 14.6	 53.1	 197.2	 [16]	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
KIDNEY	 Mouse*	 	 	 12.9	 15.8	 8.7	 7.8	 2.2	 9.5	 	 2.0	 23.3	 	 	 1.0	 16.0	 29.0	 16.5	 54.6	 177.7	 [15]	
	 Rat*		 	 0.2	 18.8	 18.5	 9.6	 6.8	 1.3	 8.6	 	 0.6	 32.9	 	 	 0.2	 2.0	 37.9	 16.4	 45.6	 123.2	 [15]	
	 Dog	+	 Brush	Border	 4.6	 30.0	 12.2	 3.1	 12.7	 	 11.5	 	 	 23.8	 	 	 	 0.5	 48.6	 15.8	 35.8	 85.4	 [125]	
	 Human	 Infant	 4.5	 21.6	 13.8	 4.9	 16.5	 1.0	 18.3	 0.6	 1.6	 14.8	 0.3	 0.3	 0.4	 1.3	 39.9	 21.4	 38.6	 79.4	 [126]	
	 Human		 Adult	 1.1	 33.7	 12.8	 3.2	 16.3	 2.7	 7.8	 0.2	 0.3	 8.9	 	 1.2	 1.0	 1.4	 47.5	 19.6	 23.5	 57.4	 [21]	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
BRAIN	&	NEURAL	 Mouse*	 Brain	 0.1	 21.9	 15.8	 10.3	 16.5	 3.5	 0.5	 	 0.4	 10.5	 0.1	 0.3	 0.2	 17.7	 37.8	 29.2	 33.2	 134.3	 [15]	
	 Rat*	 Brain	 0.3	 16.9	 13.6	 10.0	 17.0	 5.7	 0.5	 	 0.3	 13.7	 0	 0.3	 0.1	 19.3	 30.8	 29.0	 39.9	 158.4	 [15]	
	 Human*	 Cerebellum	 	 33.3	 18.9	 	 22.9	 	 0.7	 	 	 8.8	 	 	 	 15.4	 52.2	 22.9	 24.9	 104.1	 [22]	
	 Human		 Mitochondria	 	 23.9	 22.5	 	 24.5	 5.1	 0.3	 	 	 4.3	 	 	 2.5	 9.9	 46.4	 24.5	 22.1	 72.7	 [109]	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
LUNG	 Rat+	 	 2.5	 32.4	 7.9	 8.0	 18.7	 3.3	 15.2	 	 0.4	 8.7	 0.7	 	 0.7	 0.6	 42.8	 26.7	 27.8	 52.9	 [127]	
	 Human+	 	 1.6	 30.6	 9.6	 	 27.1	 2.5	 6.8	 	 	 12.0	 2.0	 0.9	 3.0	 3.9	 41.8	 27.1	 31.1	 89.1	 [17]	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
BLOOD	CELL	 Rat+	 Red	Blood	Cells	 2.5	 28.0	 13.1	 4.6	 8.3	 1.6	 8.0	 0.3	 0.7	 24.6	 0.1	 0.6	 2.4	 4.1	 43.6	 12.9	 42.4	 121.4	 [108]	
	 Human		 Red	Blood	Cells	 	 29.6	 17.1	 1.6	 19.2	 2.1	 13.3	 	 	 13.4	 0.3	 0.5	 	 2.9	 46.7	 20.8	 32.5	 74.8	 [128]	
	 Human+	 CD4+	T-Lymphocytes	 4.1	 27.2	 26.9	 5.2	 7.9	 3.2	 6.9	 	 1.5	 12.8	 0.4	 0.1	 1.3	 2.7	 58.2	 13.1	 28.9	 77.2	 [29]	
	 Human+	 CD19+	B-Lymphocytes	 5.5	 31.8	 30.5	 5.1	 7.1	 2.7	 4.7	 	 0.9	 8.2	 0.5	 0.1	 0.7	 2.0	 67.8	 12.2	 19.8	 53.0	 [29]	
	 Human+	 CD14+	Monocytes	 2.4	 20.4	 24.2	 3.5	 14.5	 5.0	 6.6	 	 1.4	 16.4	 0.2	 0.1	 2.4	 3.1	 47	 18	 35.2	 99.3	 [29]	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
GUT	 Human+	 Colorectal	Full-Thickness	 2.1	 25.3	 9.4	 5.7	 32.4	 0.7	 12.1	 0.5	 1.1	 5.1	 	 2.3	 	 2.8	 36.8	 38.1	 24.6	 55.4	 [129]	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
OTHER	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Skin	 Human+	 Basal	Layer	 8.0	 21.1	 18.0	 3.1	 15.8	 	 20.9	 0.6	 3.4	 7.8	 	 	 	 1.2	 47.1	 18.9	 33.9	 57.7	 [130]	
Aorta	Thoracic	 Human	 Tunica	Media	 6.6	 24.3	 19.8	 2.8	 19.8	 	 18.2	 	 	 8.5	 	 	 	 	 50.7	 22.6	 26.7	 43.7	 [131]	
Cervix	 Human*		 Epithelia	 	 19.7	 30.9	 	 11.9	 	 11.4	 13.2	 	 13.1	 	 	 	 	 50.6	 11.9	 37.7	 63.9	 [132]	
Pancreas	 Rat+	 	 4.1	 26.6	 6.7	 3.6	 23.7	 	 25.1	 	 	 5.8	 	 	 	 	 37.4	 27.3	 30.9	 42.5	 [133]	
Adipose	 Rat+	 	 1.1	 24.9	 3.7	 8.3	 35.5	 	 20.0	 	 	 0.3	 2.4	 	 0.1	 0.2	 31.5	 43.8	 23.0	 27.1	 [108]	
Breast		 Human*	 Glandular	tissue	 2.6	 24.9	 4.0	 7.0	 40.8	 1.2	 16.9	 	 0.2	 0.4	 	 0.3	 	 0.6	 31.5	 47.8	 19.6	 26.8	 [134]	
Heart	 Human*	 Biopsy		 2.9	 16.9	 14.1	 9.8	 7.6	 1.0	 19.3	 	 0.7	 21.3	 0.2	 0.5	 1.4	 4.5	 33.9	 17.4	 48.9	 117.7	 [23]	
Skeletal	Muscle	 Human*	 Vastus	lateralis	 2.1	 25.8	 13.4	 1.0	 12.2	 	 29.9	 	 1.2	 9.9	 0.4	 1.0	 1.2	 1.9	 41.3	 13.2	 45.5	 81.1	 [135]	













































































Mol%	 58.3	 24.6	 5.2	 6.5	 	 5.8	 	 	 	 	 	 	 	 100	 [137]	
	 HL60	(Human	
promyeloblast)	
Mol%	 52.8	 21.7	 3.9	 11.7	 	 11.1	 	 	 	 	 	 	 	 100	 [137]	
	 C1300	N18	(Mouse	
neuroblastoma)		
Wt	%	 57.0	 18.0	 5.5	 11.5	 0.09	 7.9	 	 	 	 	 	 	 	 100	 [138]	
	 NF1T	(Human	Schwann	Cell)	 Mol%	 50.0	 24.6	 3.9	 12.5	 	 9.0	 	 	 	 	 	 	 	 100	 [139]	
	 MDCK	(Dog	kidney	epithelia)	 Wt	%	 42.8	 23.2	 7.6		 8.8	 17.7	 	 	 	 	 	 	 	 	 100	 [96]	
	 HepG2	(Human)PM	 Wt%	 42.3	 27.8	 7.0	 4.4	 12.4	 6.1	 	 	 	 	 	 	 	 102	 [140]	
	 EA.hy926	(Human	
endothelia)	
	 55.1	 14.0	 3.1	 7.0	 	 23.0	 	 	 	 	 	 	 	 100	 [141]	
		 3T3	(Mouse	Fibroblast)	 Wt%	 47.6	 23.9	 		7.6	 8.5	 12.4	 	 	 	 	 	 	 	 	 100	 [96]	
	 HT29	(Human	colon)	in	
culture	
Mol%	 46.7	 22.3	 12.3	 8.3	 1.6	 6.4	 	 	 	 	 	 	 	 98	 [142]	
	 HT29	(Human	colon)	in	
tumour	in	nu/nu	Mice	













	 	 	 	 	 	 	 100	 	
Tissues		 Mouse	Brain	 P%	 45.7	 16.7	 11.8	 14.0	 	 11.5	 	 	 	 	 	 	 	 100	 [143]	
	 Rat	Brain	 P%	 36.8	 36.4	 11.8	 3.1	 4.9	 5.7	 	 	 	 	 	 	 	 100	 [144]	
	 Mouse	Kidney	 P%	 33.4	 22.2	 14.5	 14.1	 	 15.3	 	 	 	 	 	 	 	 100	 [143]	
	 Mouse	Liver	 P%	 45.7	 16.7	 11.8	 14.0	 	 11.5	 	 	 	 	 	 	 	 100	 [143]	
	 Mouse	Heart	 P%	 38.1	 22.5	 12.5	 12.1	 	 14.1	 	 	 	 	 	 	 	 100	 [143]	
	 Calf	Heart	 P%	 42.8	 26.6	 3.4	 3.4	 13.6	 9.1	 	 	 	 	 	 	 	 99	 [144]	













	 	 	 	 	 	 	 99	 	
TOTAL	LIPIDS	
Cell	Lines		 HeLa	(Human	Cervical	Cells)	 Wt%	 26.6	 11.6	 3.5ª	 	 11.5	 15.8	 12.1	 	 18.7	 	 	 	 30.8	 69.0	 [49]	
	 L-M	(Mouse	Fibroblast)	 Wt%	 38.8	 23.3	 5.1	ª	 	 8.0	 7.6	 12.7	 0.4	 1.8	 	 1.6	 0.5	 17.0	 82.8	 [145]	
	 L-929	(Mouse	Adipose)	 Wt%	 36.8	 18.7	 8.6ª	 	 9.1	 7.3	 9.5	 0.4	 6.5	 	 1.0	 2.0	 19.4	 80.5	 [49]	
	 3T3	(Mouse	Fibroblast)		 Wtl%	 37.6	 16.7	 10.2ª	 	 3.0	 8.1	 14.8	 3.3	 2.2	 	 3.0	 1.0	 24.3	 75.6	 [13]	
	 PC-3	(Human	Prostate)		 Mol%	 51.1	 13.3	 5.5	 1.0	 1.1	 6.9	 19.3	 0.2	 	 1.0	 	 0.7	 21.2	 78.9	 [146]	
	 EPC	(Carp	Epithelial	
Papiloma)	
Wt%	 21.8	 22.0	 7.1	 6.4	 3.9	 8.5	 	 	 	 	 	 	 29.9	 70.1	 [147]	
	 EPC	(Carp	Epithelial	
Papiloma)	




Trout	Keratinocytes	-	Initial	 -	 14.2	 10.1	 4.5	 1.6	 1.0	 4.9	 16.7	 5.6	 38.0	
	
	 3.4	 	 63.7	 36.3	 [48]	
	 Trout	Keratinocytes	-	14	day	 -	 30.3	 13.6	 7.6	 5.0	 1.6	 4.6	 24.6	 6.3	 3.4	 	 3.0	 	 37.2	 62.7	 [48]	
	 Trout	Keratinocytes	-	4	
month	
-	 31.2	 19.4	 7.2	 5.4	 2.5	 3.7	 23.3	 2.4	 2.7	 	 2.1	 	 30.5	 69.4	 [48]	
	 Human	Endothelia	 Wt%	 26.0	 18.1	 18.3ª	 	 	 9.2	 14.6	 6.7	 2.6	 	 4.6	 	 28.5	 71.5	 [148]	






























Tissues	 Rat	Liver	 Wt%	 55.2	 19.9	 	 4.4	 4.5	 2.1	 5.4	 1.5	 6.7	 	 0.32	 	 13.9	 86.1	 [150]	
	 Rat	Heart	 Wt%	 38.6	 33.4	 	 3.7	 12.3		 1.76	 4.1	 0.22	 3.8		 0.65	 	 1.54	 10.3	 89.7	 [150]	
	 Rat	Brain	 Wt%	 26.9	 20.5	 9.1	 3.2	 9.6	 	 30.3	 0.3	 0.3	 	 	 	 69.3	 29.1	 [151]	
	 Human	Liver	 Wt	%	 18.2	 4.9	 	 	 0.4	 1.2	 	 	 75.3	 0.1	 	 	 24.7	 75.4	 [50]	
	 Human	Atria	(microsomal)	 Wt%	 24.5	 16.8	 4.1	 6.0	 8.0	 6.9	 5.5	 2.8	 20.6	 	 4.8	 	 33.7	 66.3	 [152]	
	 Human	Ventricle	
(microsomal)	
Wt%	 34.4	 19.8	 2.6	 6.5	 10.5	 5.4	 5.2	 5.2	 6.9	 	 3.4	 	 20.7	 79.2	 [152]	
	 Human	Pineal	Gland	 Wt%	 35.4	 17.5	 7.6	 6.6	 1.9	 10.4	 12.4	 1.4	 4.1	 2.1	 	 	 20.0	 79.4	 [153]	






























	 Rat	Erythrocytes	 Wt	%	 24.1	 	 	 	 1.4	 2.0	 5.7	 16.0	 48.7	 0.5	 1.7	 	 72.6	 27.5	 [150]	










































Other		 16:0	 18:0	 Other	
n-9	 	 n-6	 n-3	
18:1	 Other		 18:2	 20:2	 20:3	 20:4	 18:3	 20:5	 22:5	 22:6	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
LIVER	
Cell	Line	(rat)	*	 H35	Hepatoma		 4.1	 20.9	 23.5	 18.1	 27.9	 0.1	 1.1	 1.0	 	 1.8	 	 0.1	 0.6	 0.8	 48.5	 46.0	 5.5	 14.5	 [44]	
Cell	Line	+		 Hep2G	 6.4	 37.0	 7.1	 15.6	 31.5	 	 1.5	 	 	 0.5	 	 0.4	 0.2	 0.3	 50.5	 47.1	 2.9	 2.9	 [101]	
Tissue	(rat)*	 Normal	 0.6	 14.3	 22.9	 5.1	 3.8	 0.5	 9.9	 	 0.8	 32.7	 0.1	 0.2	 0.8	 6.9	 37.8	 8.9	 52.5	 151.1	 [15]	
Cancer	 Rat	(cell	7288CTC	implant)	 0.5	 14.6	 22.8	 5.0	 31.6	 	 11.9	 	 	 13.6	 	 	 	 	 37.9	 36.6	 25.5	 52.7	 [155]	




1.9	 23.3	 14.8	 19.5	 23.2	 0.6	 1.6	 	 	 8.5	 0.4	 0.6	 1.9	 2.2	 42.0	 42.7	 15.2	 48.9	 [43]	
Tissue*	 Control	Subjects	(Normal)	 	 26.4	 22.7	 2.5	 23.0	 4.8	 0.8	 	 0.8	 8.9	 	 	 0.3	 8.3	 49.1	 25.5	 23.9	 86.2	 [156]	
Tissue*	 Grey	Matter	(Normal)	 10.5	 27.1	 23.6	 0.5	 18.4	 	 1.6	 	 	 6.6	 0.8	 	 	 10.9	 61.2	 18.9	 19.9	 77.5	 [157]	
Cancer*	 Glioma	 	 31.0	 15.4	 4.6	 23.6	 3.3	 3.4	 	 1.7	 10.0	 	 0.1	 1.3	 3.9	 46.4	 28.2	 23.7	 71.8	 [156]	
Cancer*	 Meningioma	 8.4	 25.5	 16.7	 0.4	 27.5	 	 5.2	 	 	 12.3	 1.2	 	 	 2.2	 50.6	 27.9	 20.9	 55.5	 [157]	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
LUNG	
Cell	line*		 A549	Alveolar	Epithelia	 37.5	 	 	 41.3	 	 0.3	 2.0	 	 0.9	 6.1	 	 0.9	 0.6	 2.9	 37.5	 41.3	 13.7	 43.8	 [119]	
Tissue+	 Normal	 1.6	 30.6	 9.6	 	 27.1	 2.5	 6.8	 	 	 12.0	 2.0	 0.9	 3.0	 3.9	 41.8	 27.1	 31.1	 89.1	 [17]	
Cancer+	 Pulmonary	Carcinoma	 1.1	 20.2	 12.1	 	 33.7	 2.9	 4.4	 	 	 15.4	 3.1	 1.5	 2.2	 3.4	 33.4	 33.7	 32.9	 97.5	 [17]	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
BREAST	
Cell	Line*	 MCF-7	Adenocarcinoma	 4.8	 13.0	 4.2	 24.8	 38.8	 	 1.6	 0.1	 0.4	 1.9	 	 	 0.7	 1.6	 22.0	 63.6	 6.3	 19.0	 [98]	
Tissue+	 Normal	(Adjacent)	 2.6	 24.9	 4.0	 7.0	 40.8	 1.2	 16.9	 	 0.2	 0.4	 	 0.3	 	 0.6	 31.5	 47.8	 19.6	 26.3	 [134]	
Cancer+	 Not	Defined	 2.3	 24.7	 6.2	 6.6	 38.7	 0.7	 15.2	 	 1.0	 2.0	 	 0.4	 	 1.3	 33.2	 45.3	 20.6	 33.4	 [134]	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
COLON	
Cell	Line	(Human)+	 HT29	Adenocarcinoma	 5.3	 26.2	 8.6	 18.1	 26.9	 	 2.1	 	 	 5.2	 	 0.6	 	 1.9	 40.1	 45.0	 9.8	 29.6	 [45]		
Cell	Line	(Human)+	 Caco	2	Adenocarcinoma	 7.8	 21.3	 17.0	 12.4	 20.4	 	 2.3	 	 	 6.5	 	 1.4	 	 1.1	 45.8	 32.8	 11.2	 32.5	 [158]	
Tissue+	 Normal	(Adjacent)	 2.1	 25.3	 9.4	 5.7	 32.4	 0.7	 12.1	 0.5	 1.1	 5.1	 	 2.3	 	 2.8	 36.8	 38.1	 24.6	 55.4	 [129]	
Cancer+		 Adenocarcinoma	 2.1	 26.4	 14.4	 2.7	 26.3	 1.6	 15.8	 	 1.5	 7.2	 	 0.3	 	 1.8	 42.9	 29.0	 28.2	 55.4	 [129]	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
STEM	CELLS	






















18:0	 18:1n-9	 18:2n-6	 18:3n-3	 18:	n-3	 20:3n-9	
	
20:4n-6	 20:5n-3	 22:6n-3	
Cell	Oxidant	Production	 HT29	 Human	Colon	 	 6%	 35%	 	 	 	 94%	 40%	 429%	 [45]	50µM		
Mitochondrial	Potential	 HT29	 Human	Colon	 	 -11%	 -18%	 	 	 	 -5%	 0	 11%	 [45]	50µM		
Mitochondrial	Potential	 Neuro-2A	 Mouse	Brain	 0	 -27%	 -24%	 	 	 	 	 	 	 [159]	70-140µM		
Oxidisability	(TBARs)	 NCTC	2544	 Human	Skin	 7%	 4%	 41%	 105%	 	 	 149%	 	 	 [160]	50µM		
Apolipoprotein	A	 HepG2	 Human	Liver	 15%	 	 12%	 3%	 7%	 	 	 5%	 11%	 [161]	50µM		
Apolipoprotein	B	 HepG2	 Human	Liver	 14%	 	 15%	 26%	 29%	 	 	 31%	 41%	 [161]	50µM		
Plasminogen	Activator	Inhibitor	
Type	1	(PAI-1)	
HepG2	 Human	Liver	 	 15%	 44%	 	 	 	 	 	 	 [101]	35µM	
Chymase		 C2	 Canine	Mast	Cells	 	 	 -16%	 -13%	 	 	 	 	 	 [162]	14µM		
Tryptase	 C2	 Canine	Mast	Cells	 	 	 41%	 -42%	 	 	 	 	 	 [162]	14µM	
Histamine	Release	 C2	 Canine	Mast	Cells	 	 	 15%	 -22%	 	 	 	 	 	 [162]	14µM	
PGE2	Production	 C2	 Canine	Mast	Cells	 	 	 -6%	 -19%	 	 	 	 	 	 [162]	14µM	
PGE2	Production	 Endothelia		 Human	Umbilical	(HUVEC)	in	
Primary	Culture	
	 	 	 	 	 	 13%	 -46%	 -29%	 [100]	10µM	
Cell	Proliferation	 Raji	 Human	B-Lymphocyte	 	 	 	 	 	 	 82%	 27%	 	 [163]	25µM	
Interlukin-10	(IL-10)	 Raji	 Human	B-Lymphocyte	 	 	 	 	 	 	 -58%	 -70%	 	 [163]	25µM	
Tumour	necrosis	factor	(TNF-a)	 Raji	 Human	B-Lymphocyte	 	 	 	 	 	 	 -30%	 -41%	 	 [163]	25µM	
Interferon-gamma	(IFN-g)	 Raji	 Human	B-Lymphocyte	 	 	 	 	 	 	 -24%	 -29%	 	 [163]	25µM	
Oncogene	HER2/neu	mRNA		 MCF-7	 Human	Breast	 	 	 -33%	 	 	 	 	 60%	 	 [164]	17µM		
Stearoyl-CoA	Desaturase	Activity		 3T3-L1	 Mouse	Adipocytes	 	 	 	 	 	 	 -60%	 	 	 [165]	300µM		
Protein	Kinase	C	(PKC)	
	IGF-1	Stimulated	
MCF-7	 Human	Breast	 	 	 67%	 56%	 	 	 	 	 	 [98]	107µM	
Mitogenic	Response	
IGF-1	Stimulated	
MCF-7	 Human	Breast	 	 	 -19%	 -30%	 	 	 	 	 	 [98]	107µM	
E-cadherin	 MCF-7	 Human	Breast	 	 	 	 	 	 87%	 	 25%	 	 [166]	50µM	
E-cadherin	 HRT-18	 Human	Colon	 	 	 	 	 	 -69%	 	 81%	 	 [166]	50µM	
Ca+	Release	Thrombin	Stimulated	 Endothelia	 Human	in	Primary	Culture	 	 	 	 	 	 -49%	 	 	 	 [56]	100µM	
Alkaline	Phosphatase	 MC3T3-E1	 Mouse	
Osteoblasts	
	 	 	 	 	 -39%	 	 	 	 [167]	10µM	
Sodium	Channel	Flux	(INa)	 hBSMCs	 Human	Bronchial	Smooth	Muscle	 -8%	 -7%	 	 	 	 	 -47%	 -64%	 -74%	 [103]	10µM	in	media	
not	supplemented		
Sodium	Channel	mRNA	 hBSMCs	 Human	Bronchial	Smooth	Muscle	 	 	 	 	 	 	 -55%	 	 	 [103]	30µM		
Na+	/Ca2+	Exchanger	 HEK293t	 Human	Kidney	 -6%	 	 	 	 	 	 -73%	 -89%	 -97%	 [104]	10µM	in	media	
not	supplemented		
Na+	Current	 HEK293t	 Human	Kidney	 1%	 9%	 41%	 60%	 	 	 	 58%	 53%	 [168]	5µM		
K+	Intracellular	 Neuro-2A	 Mouse	Brain	 3%	 8%	 2%	 	 	 	 	 	 	 [159]	70-140µM	
K+	Permeability	 Neuro-2A	 Mouse	Brain	 	 -29%	 -24%	 	 	 	 	 	 	 [159]	70-140µM	
Na+	Permeability	 Neuro-2A	 Mouse	Brain	 	 106%	 117%	 	 	 	 	 	 	 [159]	70-140µM	
Na+,	K+-ATPase	Activity	 Neuro-2A	 Mouse	Brain	 -9%	 -4%	 -8%	 	 	 	 	 	 	 [159]	70-140µM	
Percent	difference	is	relative	to	standard	culture	conditions	(at	varying	supplemented	fatty	acid	concentrations	as	indicated	in	reference	column).	
	
Figure	Legends	
	
Figure	1:	The	relative	percentage	of	saturated	(SAT),	monounsaturated	(MUFA)	and	
polyunsaturated	(PUFA)	fatty	acids	in	natural	tissues	and	cell	lines	derived	from	
mammals	(human,	monkey,	dog,	rat	and	mice).	Organs	of	origin	include;	liver,	kidney,	
brain,	lung,	blood	cells,	gut,	pancreas,	cervix,	breast	gland,	as	well	as	skeletal	muscle,	
adipose,	skin	and	aorta	for	tissues	and	larynx	for	cell	lines.	Data	is	taken	from	Tables	2	
and	3.	Horizontal	line	represent	mean	values,	N	=	30	for	tissues	and	25	for	cell	lines.			
	
Figure	2:	Relationship	between	levels	of	precursor	fatty	acids	(linoleic	and	a-linolenic	
acid)	and	one	long-chain	product	in	membrane	phospholipids	of	cells	and	tissues	of	
mammals.	(A)	show	the	relationship	between	the	n-6	essential	fatty	acid,	linoleic	acid	
(18:2n-6)	and	its	product	arachidonic	acid	(20:4n-6).	(B)	shows	the	relationship	between	
the	n-3	essential	fatty	acid,	a-linolenic	acid	(18:3n-3)	and	its	product	docosahexaenoic	
acid	(22:6n-3).	Original	organs	used	for	both	cell	lines	and	tissues	include	brain,	blood	
cells,	liver,	kidney	and	lung.	The	21	different	cell	lines	(in	closed	symbols)	were	examined	
mainly	from	humans	with	a	few	rodent	values.	The	28	natural	tissues	(open	symbols)	
were	from	species	including	rodents,	pig,	sheep,	human,	cattle	and	horse.	Note:	in	cases	
where	18:3n-3	levels	fell	below	the	detection	level	a	nominal	value	of	0.1	was	assigned.	
References	for	cell	lines	include	[29,	43,	44,	46,	47,	60,	61,	90,	96,	102,	117-119,	169,	170]	
and	for	tissues	[15-17,	21,	29,	43,	108,	125,	127,	128,	171].	
	
Figure	3:	Membrane	docosahexaenoic	acid	(DHA)	phospholipid	composition	plotted	
against	the	concentration	of	DHA	in	cell	culture	media	cross	five	different	cell	lines	(SN56	
Neuronal,	HT22	Hippocampal,	HT29	colonic;	H35	liver,	A549	lung)	from	four	different	
studies.	Values	from	[43,	45-47].	A	DHA	concentration	value	of	6	µM	was	used	for	10%	
FBS	culture	media	based	on	values	from	[9,	169,	170].	
	
Figure	4:	The	relative	percentage	of	saturated	(SAT),	monounsaturated	(MUFA)	and	
polyunsaturated	(PUFA)	fatty	acids	in	liver,	brain,	lung,	breast	and	colon,	in	natural	
tissues	and	in	situ	cancers	from	the	same	tissues	compared	against	cell	lines	derived	from	
the	same	five	tissues.	Most	values	were	from	human	sources	except	liver	that	contains	
mainly	rat	tissues	(and	one	human	cell	line	HepG2).	Values	(and	references)	are	from	
Table	5.	
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